India's Research Funding Problem and the Persistent Gap Between Universities and Industry

India's gross expenditure on research and development has sat stubbornly close to 0.65 percent of GDP for the better part of a decade, a figure that comparisons to China's roughly 2.4 percent or South Korea's nearly 5 percent make look almost quaint for an economy that aspires to be a genuine technology power. The number gets cited often enough in policy debates that it risks becoming background noise, a statistic everyone nods at without examining its composition. That composition matters more than the headline figure, because it reveals a structural problem that simply increasing the budget allocation, however necessary, would not by itself resolve.

Who actually pays for research in India

In most advanced research economies, private industry funds the majority of national research and development spending, reflecting a mature innovation ecosystem where companies invest in R&D because they expect to capture the commercial returns; in the United States and South Korea, industry funds somewhere between sixty and seventy-five percent of total research spending. In India, the pattern inverts: the central government, through bodies like the Department of Science and Technology, the Council of Scientific and Industrial Research, and the Defence Research and Development Organisation, accounts for the large majority of research funding, while private industry's contribution has remained persistently below thirty-seven percent by most recent estimates, and a substantial share of even that private spending comes from a handful of large firms in pharmaceuticals and automotive components rather than a broad base of research-intensive companies.

Why Indian industry underinvests in research

This is not simply a matter of Indian companies being insufficiently ambitious; it reflects real structural incentives. A large share of Indian industrial output, historically, has competed on cost and process efficiency rather than on proprietary technology, particularly in sectors like textiles, chemicals and low-end manufacturing where the competitive return on an incremental research rupee is genuinely lower than the return on the same rupee spent on capacity expansion or supply chain efficiency. India's pharmaceutical industry, by contrast, which does compete substantially on formulation research and biosimilar development, is also the sector that invests most heavily in R&D relative to revenue among Indian industries, a pattern that supports the underlying logic: research investment follows where the commercial return on research specifically is highest, and for much of the Indian economy, that return has simply not been there yet.

The university-industry disconnect

The second, less discussed half of the problem is that even the research India does fund tends to happen in institutional silos that rarely talk to each other. Indian universities, including many of the Indian Institutes of Technology that produce genuinely capable researchers, generate patents and publications at rates that compare respectably to international peers, but the rate at which that research translates into licensed technology actually used by Indian companies remains low, a gap that studies by NITI Aayog and independent researchers attribute to weak technology transfer infrastructure, unclear intellectual property arrangements between institutions and industry, and a broader cultural gap where academic research incentives, driven by publication metrics, and industry's commercial timelines, driven by quarterly product cycles, simply do not align without deliberate institutional bridging.

What the Anusandhan National Research Foundation was meant to fix

The government's 2023 creation of the Anusandhan National Research Foundation, with a mandate to catalyse and fund research across scientific disciplines and an explicit goal of channelling a much larger share of its roughly fifty-thousand-crore five-year funding envelope from private sources rather than government budgetary support, represents a direct acknowledgement of this structural problem. The ANRF's design, modelled loosely on the United States National Science Foundation but with a heavier emphasis on leveraging private capital, is a reasonable structural response, though its early implementation has faced the familiar challenge that mobilising committed private research funding requires companies to see a credible pipeline of investable research first, a chicken-and-egg problem that funding architecture alone does not resolve.

Comparative lessons from Israel and South Korea

Israel's research ecosystem, often cited as a model, offers an instructive comparison precisely because it built strong university-industry linkages through deliberate policy instruments, including the Office of the Chief Scientist's matching-grant programmes that shared research risk between government and private companies, and a technology transfer culture at institutions like the Technion that treated commercialisation as a core academic function rather than an afterthought. South Korea's chaebols, while criticized on other grounds, invested heavily in in-house research precisely because government industrial policy in the 1970s and 80s made technological upgrading a condition of continued state support and credit access, creating an incentive structure that pushed private capital toward research at a scale market forces alone might not have produced.

What a workable Indian version would require

An Indian equivalent does not need to replicate either model exactly, but it would need to address the same underlying coordination failure: Indian companies do not fund enough university research partly because they do not trust the commercialisation pipeline to deliver usable outcomes on a viable timeline, and Indian universities do not orient enough research toward industry-relevant problems partly because academic incentive structures do not reward it. Breaking this cycle requires more than funding; it requires technology transfer offices with genuine negotiating capacity and legal expertise, currently underdeveloped at most Indian universities outside the top IITs, matching-grant mechanisms that share risk the way Israel's did, and a tenure and promotion system in Indian academia that gives some weight to patents, industry consulting and applied research outputs alongside the publication count that currently dominates evaluation.

None of this is a case against increasing the overall research budget, which remains genuinely too low relative to India's economic ambitions. It is a case that the 0.65 percent figure, taken alone, obscures the more important question of institutional design. A country could double its research spending to 1.3 percent of GDP and still see limited commercial payoff if the university and industry sides of that spending continue operating as parallel, largely non-communicating systems. The funding gap is real and worth closing. The trust and translation gap between India's researchers and its companies is the harder problem, and it is the one that determines whether additional funding, when it eventually arrives, actually produces the innovation dividend the country is hoping for.